Gapping up
In reaction to earnings/guidance:
- RH +17%, SLQT +13.2%, VRNT +10%, AGX +9.8%, NCNO +5.1%, AAN +4.3%, LAKE +3.8%, DGX +3.2% (raises FY20 EPS and revs guidance) TSM +1.1% (Aug sales), LSTR +0.9%, ENR +0.9%
Other news:
- VRTU +23.3% (to be acquired by Baring Private Equity Asia for $51.35/share in cash)
- CBD +14.7% (approved initiating a study to segregate its cash and carry unit through a partial spin-off of the Company)
- IMTX +11.4% (provided an update on its fourth ACTengine cell therapy program, IMA204)
- INVA +6.7% (Innoviva and GlaxoSmithKline plc (GSK) receive FDA approval for Trelegy Ellipta)
- MD +5.8% (announces agreement to sell MEDNAX Radiology Solutions to Radiology Partners)
- TXMD +3% (announced patent update for ANNOVERA)
- PTON +2.9% (reports earnings after hours tonight)
- NNOX +2.7% (submitted official response to accredited Review Organization under the FDA Third Party Review Program)
- FBRX +2.2% (announced publication of Phase 1/2a data for FB-401), SSL +1.8% (sells air separation units business to Air Liquide)
- CGC +1.5% (announced the launch of Martha Stewart CBD-- a new line of hemp-derived wellness supplements)
- AZN +1.1% (reportedly denied COVID-19 vaccine trial patient suffered from transverse myelitis)
Analyst comments:
- BBCP +7.6% (upgraded to Buy from Neutral at B. Riley FBR)
- SPOT +4.1% (upgraded to Outperform from Neutral at Credit Suisse)
- HWM +2.3% (upgraded to Overweight from Underweight at Barclays)
- SAFM +2% (upgraded to Buy from Neutral at Goldman)
- NVS +1% (upgraded to Buy from Neutral at UBS)